Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine CandidateGlobeNewsWire • 01/13/20
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial ForecastGlobeNewsWire • 01/13/20
Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/06/19
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine CandidateGlobeNewsWire • 11/22/19
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor DayGlobeNewsWire • 11/21/19
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 11/07/19
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine CandidateGlobeNewsWire • 10/10/19
Emergent Biosolutions (EBS) Down 0.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/31/19
Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/03/19